Holen Sie sich die Stockscreener-App
66.34
1.42%
0.93
Vorhandelsmarkt:
61.28
-5.06
-7.63%
Schlusskurs vom Vortag:
$65.41
Offen:
$65.12
24-Stunden-Volumen:
198.25K
Relative Volume:
0.57
Marktkapitalisierung:
$1.44B
Einnahmen:
$486.82M
Nettoeinkommen (Verlust:
$18.78M
KGV:
80.90
EPS:
0.82
Netto-Cashflow:
$100.45M
1W Leistung:
+3.66%
1M Leistung:
+1.19%
6M Leistung:
+14.06%
1J Leistung:
+6.88%
1-Tages-Spanne:
$64.89
$66.66
1-Wochen-Bereich:
$63.60
$68.60
52-Wochen-Spanne:
$52.50
$77.00
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Vergleichen Sie ANIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
66.34 | 1.39B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals Announces Results from NEW DAY Clinical - GlobeNewswire
Clinical Trial Reveals ILUVIEN Cuts DME Treatment Burden: Patients Need Only 2.8 vs 7.5 Injections - Stock Titan
Is ANI Pharmaceuticals Inc. a good long term investmentExponential return rates - jammulinksnews.com
What analysts say about ANI Pharmaceuticals Inc. stockRapid growth opportunities - jammulinksnews.com
ANI Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - Autocar Professional
What drives ANI Pharmaceuticals Inc. stock priceBreakout profit opportunities - Autocar Professional
Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX), Abbott Laboratories (ABT) and ANI Pharmaceuticals (ANIP) - The Globe and Mail
Teacher Retirement System of Texas Has $303,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Healthcare Stocks to Watch: Gain Therapeutics, Abbott Laboratories, and ANI Pharmaceuticals - AInvest
Should I buy ANI Pharmaceuticals Inc. stock before earningsLow Risk Profit Ideas - Newser
How ANI Pharmaceuticals Inc. stock performs during market volatilityShort Term Risk Controlled Alerts - Newser
Why ANI Pharmaceuticals Inc. stock attracts strong analyst attentionLow Risk High Reward Picks - Newser
What makes ANI Pharmaceuticals Inc. stock price move sharplyReliable Low Risk Signals - Newser
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of “Buy” from Analysts - Defense World
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Bought by Principal Financial Group Inc. - Defense World
Brokers Offer Predictions for ANIP Q2 Earnings - Defense World
HC Wainwright Begins Coverage on ANI Pharmaceuticals (NASDAQ:ANIP) - Defense World
HC Wainwright Initiates ANI Pharmaceuticals at Buy With $84 Price Target - MarketScreener
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Boosted by Allspring Global Investments Holdings LLC - Defense World
GAMMA Investing LLC Has $95,000 Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Illinois Municipal Retirement Fund Has $546,000 Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals: Unlocking Rare Disease Growth Through Strategic Investor Engagement - AInvest
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
State of Alaska Department of Revenue Trims Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Raymond James Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP) - The Globe and Mail
ANI Pharmaceuticals Inc (ANIP) Shares Up 2.7% on Jun 18 - GuruFocus
ANI Pharmaceuticals (ANIP) Reveals New Preclinical Findings on Cortrophin Gel | ANIP Stock News - GuruFocus
ANI Pharmaceuticals Announces Presentation of New Preclinical Data - The Manila Times
Breakthrough Arthritis Treatment Data: Cortrophin Gel Successfully Reduces Joint Inflammation in Preclinical Study - Stock Titan
GAMMA Investing LLC Purchases 94,464 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 13,948 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
ANI Pharmaceuticals at Jefferies Conference: Strategic Growth in Rare Diseases - Investing.com Canada
ANI Pharmaceuticals To Present At Jefferies Global Conference; Webcast At 2:35 PM ET - Nasdaq
ANI Pharmaceuticals Inc (ANIP) Shares Up 3.19% on Jun 2 - GuruFocus
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Nuveen Asset Management LLC - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
BNP Paribas Financial Markets Reduces Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewswire
Bank of America Corp DE Raises Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):